Pharmacokinetics of temocapril hydrochloride,a novel angiotensin converting enzyme inhibitor,in renal insufficiency |
| |
Authors: | Prof Mitsuyoshi Nakashima PhD MD J Yamamoto M Shihata T Uematsu H Shinjo T Akahori H Shioya K Sugiyama Y Kawahara |
| |
Institution: | (1) Department of Pharmacology, Hamamatsu University School of Medicine, 3600 Handa-cho, 431-31 Hamamatsu, Japan;(2) Department of Internal Medicine, Kakegawa City Hospital, Kakegawa, Japan;(3) Product Development Laboratories Sankyo Co. Ltd., Tokyo, Japan;(4) New Drug Development Department I, Sankyo Co., Ltd., Tokyo, Japan |
| |
Abstract: | Summary The pharmacokinetics of temocapril hydrochloride, a novel prodrug-type angiotensin-I converting enzyme (ACE) inhibitor, has been studied in patients with mild (Group II) to severe (Group III) renal insufficiency in comparison with subjects with normal renal function (Group I).The pharmacokinetic parameters of the active diacid metabolite, including Cmax, AUC and half-life (t1/2), showed only slight changes between the three groups: AUC (0– ) was significantly larger in Group III than Group I, and t1/2 tended to be prolonged in Group III, but the change was not significant.The urinary recovery of the diacid was significantly decreased in Group III. (Group I, 28.1 %, Group II, 21.6 %, Group III, 12.8 %). Compared with other ACE inhibitors, which are mainly excreted through the kidney, the plasma concentration of the active diacid metabolite was hardly influenced by renal function. It was speculated that lowering of the dose of temocapril might be recommended only in patients with severe renal insufficiency. |
| |
Keywords: | Temocapril Renal insufficiency angiotensin-I converting enzyme inhibitor pharmacokinetics |
本文献已被 SpringerLink 等数据库收录! |
|